Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SSP Aims at ¥2 Bil. with Switch OTC Version of Diclofenac
May 4, 2009
- PhRMA to Support NHI Price Maintenance System: Mr Sekiguchi
May 4, 2009
- Magnesium Oxide Should Remain Class 3 OTC Drug: Society
May 4, 2009
- Korosho to Speed Up Development of Anticancer, Pediatric Drugs Using Supplementary Budget
May 4, 2009
- Focusing on the Task at Hand
May 4, 2009
- More Companies Show Interest in Collaborative Multinational Trials: Mr Nakagaki
May 4, 2009
- Taisho: Switch OTC Drug Containing Tiquizium Bromide
May 4, 2009
- NBI's Telmisartan + HCT Combinations Approved
May 4, 2009
- Bonoteo Prevents Fractures in Severe Osteoporosis Patients
May 4, 2009
- REGULATORY NEWS IN BRIEF
May 4, 2009
- Explanation of Steroids Required to Overcome Patient's Anxieties
May 4, 2009
- Working Hours of Obstetricians Longest in Japan
May 4, 2009
- TOPICS 2 articles
May 4, 2009
- Takeda Deals with Soaring R&D Costs through 2 Strategies
May 4, 2009
- Sanofi-aventis Aims at No. 5 Place in Japan in 5 Years: Dr Chocat
May 4, 2009
- Enhance Japan's Presence in Multinational Clinical Trials
May 4, 2009
- Market for Drugs for Hyperlipidemia to Exceed ¥400 Bil. in 2013: Fuji-Keizai Data Book
May 4, 2009
- NEDO to Start Large-Scale Clinical Trial on AD
May 4, 2009
- Shionogi to Develop In-house Products by Sugar Chain Analysis, Molecular Imaging
May 4, 2009
- Large-Scale Trial on Risk of Bone Fractures due to TZD Underway in Europe
May 4, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…